Awards & Advancement

Andrew Witty to retire from GSK in March 2017

Thursday, March 17, 2016

In the publication of its 2015 Annual Report to shareholders, GlaxoSmithKline has announced that Sir Andrew Witty, CEO, has indicated to the board his intention to retire from the company in early 2017. The board has agreed that he will retire on March 31. The board will now conduct a formal search for a successor and will consider internal and external candidates for the role.

[Read More]

INC Research appoints Judith Ng-Cashin chief scientific officer

Monday, March 14, 2016

INC Research, a, global phase I to IV CRO, has appointed Judith Ng-Cashin, M.D., as chief scientific officer. Dr. Ng-Cashin will lead the integration of the Company’s industry-recognized therapeutic and medical/scientific expertise for phase I to IV clinical trials. She will be responsible for scientific, medical and ethical governance matters, including collaboration with key medical and scientific stakeholders to strengthen INC’s position as a collaborative partner to clinical practice, sponsor and academic organizations.

[Read More]

Greenphire appoints Wayne Baker chief commercial officer

Monday, March 14, 2016

Greenphire, a global clinical payment solutions provider, has appointed Wayne Baker as chief commercial officer to lead the commercial strategy of the rapidly growing organization worldwide. Wayne brings more than 25 years of global commercial experience in technology and life science industries, most recently serving as the senior vice president and chief sales officer at Advanced Health Media (AHM).

[Read More]

2015 Discovery Fast Track Challenge winners announced by GSK

Friday, March 4, 2016

GlaxoSmithKline has announced the winners of its third Discovery Fast Track Challenge. The program is sponsored by GSK’s Discovery Partnerships with Academia (DPAc) group to provide an opportunity for academic researchers in Europe and North America to collaborate with GSK and explore novel ideas for potential medicines. Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America. The selected proposals cover research related to discovery of potential new treatments for cancer, inflammatory bowel disease, HIV and kidney disease.

[Read More]

Pete Nicholas to retire at Boston Scientific

Monday, February 29, 2016

Pete M. Nicholas, the company’s co-founder and chairman of its board, will retire from the board of Boston Scientific in May. Nicholas served as Boston Scientific’s chief executive officer and co-chairman of the board since its founding in 1979. In 1995, Pete stepped down as CEO and became its chairman. During his almost 40 years of leadership, the company grew to become a global leader in the field of interventional medicine, improving the lives of patients worldwide.

[Read More]